Brentuximab Vedotin With Dacarbazine or Nivolumab as Front-Line Therapy in Chemotherapy-Ineligible Older Patients With Classical Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy in older patients ineligible for chemotherapy
Blood 2023 Nov 09;[EPub Ahead of Print], JW Friedberg, RE Bordoni, D Patel-Donnelly, T Larson, J Goldschmidt, R Boccia, VJM Cline, A Mamidipalli, J Liu, A Akyol, C YasenchakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.